Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Clinical trial NCT04123379 · COMPLETED
Trial details
- NCT number
- NCT04123379
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-05
- Primary completion
- 2023-08-24
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.